Jump to any asset
850 assets, updated daily
As of September 10, 2026, Biogen Inc. (BIIB) trades at $215.43. CleaRank Financial AI rates it Buy with a fair value of $240.00, 11.4% above the current price. Wall Street's consensus target is $240.00 across 35 analysts. RSI at 37 is in neutral territory, and the price is above its 50-day average of $209.34.
Biogen Inc. (BIIB)
Biogen Inc. NASDAQ
$215.43
4.700 (2.23%)
Latest Price
AI Analyst Consensus
68 / 100
Biogen Inc. (BIIB) is trading at $210.73, with its price currently above its 50-day and 200-day moving averages ($209.34 and $191.48), suggesting a generally positive technical trend. The company has demonstrated strong earnings performance, notably beating estimates by 77.34% in its most recent quarter, with actual EPS of $3.6 against an estimate of $2.03. Revenue growth is projected to be 4.00% for the current quarter and 14.00% for the next quarter, indicating a rebound in sales momentum. Wall Street analysts maintain a positive outlook, with a consensus rating of 'Buy' and a median price target of $240, implying a 13.9% upside. The primary risk remains the moderate insider selling signal, with total sales of $1.8 million against $152,144 in purchases.
BIIB Price Analysis
Market Metrics
Open
$209.92
Day Range
$208.93 to $216.70
Prev Close
$210.73
Volume
928.0K
52-Week Range
$131.52 to $225.80
Market Cap
$31.14B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Valuation is broadly in line with sector peers (0.0112% difference), suggesting fair market pricing relative to industry standards.
BIIB Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 5 quarters, BIIB beat estimates 4 times. However, the stock fell 3 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
BIIB Analysis
Company's Health
4/5
12-Month Analyst Target
+11.41% Upside
Median of 35 analysts (12-month)
$240.00
AI Technical Analysis
Biogen Inc. (BIIB) is trading above its 50-day and 200-day moving averages ($209.34 and $191.48), indicating an overall bullish trend. However, the stock is currently below its 20-day EMA ($215.51) and its RSI is at 37.13, signaling bearish momentum and suggesting a potential for short-term pullbacks. Volume on the latest day was 694,600, slightly above the average of 687,460, indicating moderate investor interest. Key support levels are near the 50-day SMA, while resistance may be found near the 20-day EMA and previous highs.
ProTips
- Monitor Biogen's pipeline developments and regulatory approvals for key drugs, as these are critical catalysts for future revenue growth.
- Given the bearish RSI momentum, consider waiting for a technical pullback to a support level near the 50-day SMA ($209.34) for a more favorable entry point.
- The moderate insider selling suggests caution; ensure any investment aligns with your personal risk tolerance and diversification strategy.
Key Catalysts
Bullish
Strong Earnings Beat in Latest Quarter
Biogen Inc. reported EPS of $3.60, significantly exceeding analyst estimates of $2.03 by 77.34% for the quarter ending July 29, 2026, indicating strong operational performance.
Source: Company Earnings ReportBullish
Positive Analyst Rating Upgrades
Several analysts have recently upgraded or maintained 'Outperform'/'Buy' ratings, such as Wolfe Research upgrading to 'Outperform' and Truist Securities upgrading to 'Buy', reflecting positive sentiment on the stock's prospects.
Source: Analyst RatingsBearish
Moderate Insider Selling Signal
Insiders have sold a net of $1.8 million worth of shares against $152,144 in purchases, indicating a moderate sell signal from management.
Source: Insider TransactionsNeutral
Projected Revenue Growth Slowdown
While near-term revenue growth is positive, projections for next year indicate a slowdown to 2.00%, which could impact future valuation multiples if not offset by new product success.
Source: Revenue EstimatesMarket Outlook
Biogen Inc. (BIIB) is expected to maintain its current upward trajectory, with a base case projection of $219.80 by 2030, supported by its recent strong earnings performance and positive analyst sentiment. The company's ability to consistently beat earnings estimates, coupled with projected revenue acceleration in the near term, provides a foundation for continued growth. The median analyst target price of $240 suggests a potential upside of 13.9% from current levels, reflecting confidence in the company's product pipeline and market position. However, potential headwinds include a projected slowdown in revenue growth to 2.00% for next year and moderate insider selling activity. Investors should monitor the company's ability to secure new contracts or launch innovative therapies to sustain growth beyond the next fiscal year. A downside scenario could see the price fall to $78.73, highlighting the importance of risk management and diversification.
Key Statistics
| Market Cap | 31.14B |
|---|---|
| P/E Ratio | 37.74 |
| EPS (TTM) | 5.63 |
| Dividend Yield | 0.00% |
| 52 Week High | 225.80 |
| 52 Week Low | 131.52 |
Biogen Inc. (BIIB) exhibits a P/E ratio of 37.74, which is in line with the sector average of 37.74, suggesting fair valuation relative to its peers. The company's EPS stands at $5.63. Revenue growth is projected at 4.00% for the current quarter and 14.00% for the next, indicating an acceleration in sales. While the P/E ratio is not excessively high, the moderate revenue growth for the current year (6.00%) warrants attention, especially when considering the forward growth for next year is projected to slow to 2.00%. The company's balance sheet strength and profitability margins will be key factors in sustaining its valuation.
Earnings & Growth Analysis
Biogen Inc. (BIIB) delivered a strong earnings surprise in its most recent quarter ending July 29, 2026, reporting actual EPS of $3.60 against an estimate of $2.03, a significant beat of 77.34%. This follows a pattern of positive earnings surprises in previous quarters, with the exception of a slight miss in the quarter ending March 30, 2026. The company's ability to consistently exceed earnings expectations, particularly in the latest report, suggests effective operational management and product demand.
Key Risks
The primary risk for Biogen Inc. (BIIB) stems from insider selling, with total sales of $1.8 million significantly outweighing purchases of $152,144, indicating a moderate sell signal. Additionally, the projected revenue growth for next year is only 2.00%, which could limit upside potential if not offset by new product launches or market expansion. The stock's current RSI of 37.13 also suggests bearish momentum, hinting at potential near-term price weakness.
Technical Indicators
| RSI (14) | 37.13 |
|---|---|
| MACD | 2.43 |
| SMA 50 | 209.34 |
| SMA 200 | 191.48 |
RSI
Bearish
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($209.34) above the 200-day SMA ($191.48), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.26
Weak correlation
Nasdaq 100 (QQQ)
+0.17
Weak correlation
Bitcoin (BTC)
-0.08
Weak correlation
Gold (XAU)
+0.02
Weak correlation
Check Custom Correlation
Calculating correlation...
BIIB Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
🟢 LONG ENTRY (click to switch)
CONSERVATIVE
$211.12
2% below current price (Pullback entry)
Lower risk, wait for pullback
AGGRESSIVE
$215.43
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$199.34
MAX LOSS
-5.6%
Volatility-Adjusted Stop Loss
Calculated based on RSI (37.1) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$221.68
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$232.23
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$242.79
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for BIIB is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 11, 2026.Growth of $10,000
A $10,000 investment in BIIB in September 2016 would be worth about $6,963 today, compared with about $35,241 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in BIIB today could grow to about $11,111 by 2036 in the base case, with a bull case near $56,329 and a bear case around $2,192. Projections are statistical simulations, not guarantees.
BIIB Stock Price Prediction: 2030
CleaRank's simulation projects a price near $225 for BIIB by 2030 in the base case, from $215 today (1.0x over 4 years). The downside path ends near $80.49. These are outcomes of a Monte Carlo simulation run on BIIB's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $130 | $218 | $364 |
| 2028 | $106 | $220 | $455 |
| 2029 | $91.39 | $222 | $541 |
| 2030 | $80.49 | $225 | $627 |
| 2031 | $72.06 | $227 | $716 |
| 2032 | $65.26 | $229 | $807 |
| 2033 | $59.63 | $232 | $902 |
| 2034 | $54.87 | $234 | $1,001 |
| 2035 | $50.78 | $237 | $1,105 |
| 2036 | $47.21 | $239 | $1,213 |
Method: 10,000 simulated price paths using BIIB's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
BIIB Insider Trading Analysis
Bought
$152.1K
2 Transactions
Sold
$1.8M
6 Transactions
Insiders
20
Active Traders
Avg Transaction
$238.4K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 7, 2021 | SANDROCK ALFRED W JR
Officer
|
Sell | 7.7K | $3.4M |
| Jul 19, 2017 | ALEXANDER SUSAN H
Officer
|
Sell | 7.8K | $2.2M |
| Mar 18, 2019 | PANGIA ROBERT W
Director
|
Sell | 6.1K | $2.0M |
| Jan 9, 2018 | PANGIA ROBERT W
Director
|
Sell | 5.8K | $1.9M |
| Nov 14, 2022 | GREGORY GINGER
Officer
|
Sell | 5.6K | $1.7M |
| Oct 27, 2022 | ALEXANDER SUSAN H
Officer
|
Sell | 5.5K | $1.6M |
| Jul 25, 2017 | ALEXANDER SUSAN H
Officer
|
Sell | 5.0K | $1.4M |
| Jun 7, 2021 | GUINDO CHIRFI
Officer
|
Sell | 3.1K | $1.4M |
| Mar 7, 2025 | SHERWIN STEPHEN A
Director
|
Sell | 8.8K | $1.3M |
| Apr 28, 2023 | GREGORY GINGER
Officer
|
Sell | 2.7K | $804.3K |
Page 1 of 1
Frequently Asked Questions
Is Biogen Inc. (BIIB) stock a buy right now?
Biogen Inc. (BIIB) is currently rated a 'Buy' by Wall Street analysts, with a consensus score of 68 and a median price target of $240, suggesting a potential 13.9% upside from its current price of $210.73. The stock is trading above key moving averages, and recent earnings have shown strong beats.
What is Biogen Inc.'s (BIIB) price target for 2030?
Based on Monte Carlo simulations, Biogen Inc.'s (BIIB) projected price for 2030 is $219.80 as a base case, with a downside projection of $78.73 and an upside projection of $613.61. These are statistical outcomes, not guaranteed price targets.
How did Biogen Inc. (BIIB) perform in its latest earnings report?
In its most recent earnings report on July 29, 2026, Biogen Inc. (BIIB) reported an EPS of $3.60, significantly exceeding the analyst estimate of $2.03 by 77.34%. This strong performance contributed to a modest price change of -0.62% on the day.
What are the key risks facing Biogen Inc. (BIIB)?
Key risks for Biogen Inc. (BIIB) include moderate insider selling totaling $1.8 million, a projected slowdown in revenue growth to 2.00% for next year, and bearish momentum indicated by its RSI at 37.1.
How does Biogen Inc.'s (BIIB) valuation compare to its sector averages?
Biogen Inc.'s (BIIB) P/E ratio of 37.74 is currently in line with the sector average of 37.74, suggesting its valuation is comparable to other companies in the Drug Manufacturers - General industry.
What is the revenue growth outlook for Biogen Inc. (BIIB)?
Biogen Inc. (BIIB) is expected to see revenue growth of 4.00% for the current quarter and a more substantial 14.00% for the next quarter. However, the outlook for next year projects a slower growth rate of 2.00%.
What is the consensus rating for Biogen Inc. (BIIB) among analysts?
The consensus rating for Biogen Inc. (BIIB) among 35 analysts is 'Buy', with 3 rating it 'Strong Buy', 20 'Buy', 11 'Hold', and 1 'Sell'.